Filing Flows › Sanofi (SNY) › R&D spending
Sanofi (SNY) R&D spending by quarter
Sanofi's R&D spending was $1.8B in Q3 2026 (third quarter 2026), -17% from Q2 2026. Over the last 6 quarters it ranged from $1.7B (Q1 2026) to $2.3B (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $1.8B | -17% | +0.8% |
| Q2 2026 | $2.2B | +28% | +17% |
| Q1 2026 | $1.7B | -24% | — |
| Q4 2025 | $2.3B | +25% | — |
| Q3 2025 | $1.8B | -4% | — |
| Q2 2025 | $1.9B | — | — |
Q3 2026 at a glance
Sanofi, Q3 2026: revenue $14.4B (+16% year over year), operating margin 30.1%, net earnings $3.0B, operating cash flow $3.9B. The chart follows the revenue to costs, profit and cash.
Questions
What is Sanofi's R&D spending?
Sanofi's R&D spending was $1.8B in Q3 2026 (third quarter 2026), -17% from Q2 2026.
How has Sanofi's R&D spending changed?
Over the last 6 quarters it ranged from $1.7B (Q1 2026) to $2.3B (Q4 2025).